Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors

✍ Scribed by Noboru Yamamoto; Atsushi Horiike; Yasuhito Fujisaka; Haruyasu Murakami; Tatsu Shimoyama; Yasuhide Yamada; Tomohide Tamura

• Publisher: Springer
• Year: 2007
• Tongue: English
• Weight: 367 KB
• Volume: 61
• Category: Article
• ISSN: 0344-5704
• DOI: 10.1007/s00280-007-0494-8